Dupixent surges while EYLEA HD takes the lead
- Dupixent global sales hit $6 billion in Q2 2026, growing 38% year over year.
- EYLEA HD sales surpassed legacy EYLEA in the United States for the first time.
- Regeneron fully repaid its Sanofi development balance, boosting future profit sharing.
- The FDA delayed a decision on the EYLEA HD pre-filled syringe until year end.
- Finn sees a balanced picture with strong financial health offsetting pipeline questions.
A stronger core, a thinner pipeline
Regeneron's growth engine is firing on its main cylinders. Dupixent, sold with Sanofi, reached $6 billion in global Q2 2026 net sales and grew 38%. The company also fully repaid its Sanofi development balance, which means a larger share of profits flows to Regeneron starting in the third quarter.
The U.S. eye franchise reached a major turning point. EYLEA HD generated $596 million in Q2 2026, beating the $412 million from legacy EYLEA. This proves the company can switch patients to the newer drug, even as older EYLEA sales fall 45% year over year against heavy competition.
However, challenges remain. The FDA delayed its decision on a pre-filled syringe for EYLEA HD to the end of the year, which keeps a key defense tool out of doctors' hands. Multiple new biosimilars are expected in late 2026, which will test how well the combined eye franchise can hold its ground.
Following the fianlimab trial failure earlier this year, the pipeline has fewer near-term catalysts. The stock story relies on Dupixent growing even larger, EYLEA HD fending off new rivals, and upcoming data for drugs like garetosmab and cemdisiran proving the pipeline can still deliver.
Science, sales, and partners
Regeneron is a fully integrated biotech company. That means it discovers drugs, tests them, makes them, and sells some of them itself. Its research engine uses antibody discovery tools to create new drug candidates.
Money comes from two main places. First, Regeneron records direct product sales in the United States for drugs like EYLEA, EYLEA HD, Libtayo, and Praluent. In Q2 2026, combined U.S. sales for the EYLEA franchise were just over $1 billion.
Second, Regeneron earns collaboration revenue from partners. Sanofi is the most important partner because it records Dupixent sales globally and shares profits with Regeneron. Bayer records EYLEA sales outside the United States and shares profits.
This model works when the science keeps producing big products and partners sell them well. It breaks when a key drug faces biosimilars, when a trial fails, or when a contract manufacturer delays an important product form.
The drugs that matter
Dupixent
Dupixent treats allergic and inflammatory diseases. Sanofi records sales, while Regeneron earns its share of the profits.
EYLEA HD and EYLEA
These eye drugs treat diseases such as wet age-related macular degeneration. EYLEA HD is now the larger seller in the U.S., replacing the declining legacy product.
Libtayo
Libtayo is a cancer drug used in non-small cell lung cancer and other settings. Regeneron records global net product sales, which grew 29% year over year in Q2 2026.
Praluent
Praluent lowers LDL cholesterol. Regeneron handles the U.S. market, while Sanofi handles sales outside the United States and pays Regeneron royalties.
Garetosmab and cemdisiran
These are pipeline assets that could matter over the next few years. Near-term watch points include garetosmab in FOP and cemdisiran in myasthenia gravis.
Revenue split, not operating segments
Regeneron reports one operating segment. The mix below reflects recent revenue trends, showing where money comes from rather than separate business units.
What could go wrong
Dupixent concentration
High impact · Medium oddsThe bull case leans heavily on Dupixent. It is growing quickly, but any slowdown would be felt across the whole company. Regeneron's Sanofi collaboration revenue is its largest growth engine.
EYLEA biosimilar wave
High impact · High oddsMultiple 2-mg biosimilars are expected to launch in the second half of 2026. Legacy EYLEA is already falling 45% year over year, and these new rivals will test whether EYLEA HD can defend the total franchise.
Pre-filled syringe delay
Medium impact · Medium oddsThe FDA delayed its decision on the EYLEA HD pre-filled syringe past the expected Q2 date. The company now hopes for approval by year end. A pre-filled syringe is needed to make the drug easier for doctors to use.
Pipeline gap after fianlimab
High impact · Medium oddsThe fianlimab melanoma study failure removed a major near-term catalyst. The company needs other pipeline drugs to prove they can become the next major growth driver.
In one breath
Why is Dupixent so important to Regeneron?
Dupixent is Regeneron's main growth driver through its Sanofi partnership. In Q2 2026, global Dupixent net sales were $6 billion and grew 38% on a constant currency basis.
What is happening to EYLEA?
EYLEA HD is growing and just became the larger product. In Q2 2026, EYLEA HD U.S. sales were $596 million, while legacy EYLEA U.S. sales fell 45% year over year to $412 million.
Why did the fianlimab news matter?
Fianlimab plus Libtayo was a major oncology hope for metastatic melanoma. Its Phase 3 failure removed a near-term catalyst and raised a bigger question about which pipeline drug can become the next major growth driver.
